Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079312 | 0.82 | PDE2A (0.34) | PDE2AHTR2AHTR2BHTR2CKIF11 | |
| SCHEMBL6576802 | 0.82 | RORC (0.34) | TSHRALDH1A1 | |
| SCHEMBL207047 | 0.77 | CYP1A2 (0.30) | — | |
| SCHEMBL95846 | 0.72 | KIF11 (0.36) | PDE2AHTR2AHTR2BHTR2CMAPT | |
| SCHEMBL27999512 | 0.72 | PDE2A (0.37) | PDE2ASMN1; SMN2LMNASLC6A4DRD3 | |
| SCHEMBL3104276 | 0.72 | HTR2A (0.41) | PDE2AHTR2AHTR2BHTR2CSIGMAR1 | |
| SCHEMBL15352508 | 0.72 | PDE2A (0.38) | PDE2AHTR2AHTR2BHTR2CNPSR1 | |
| SCHEMBL149760 | 0.70 | TSHR (0.37) | PDE2AHTR2CKIF11TSHRMAPK1 | |
| SCHEMBL146433 | 0.70 | PDE2A (0.37) | PDE2AHTR2CSIGMAR1KIF11TSHR | |
| SCHEMBL1776424 | 0.70 | TRPA1 (0.35) | HTR2BLMNAADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105636955-A | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL CO | 2016-06-01 | — | — | CN | disclosed |
| CN-104245689-A | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL CO | 2014-12-24 | — | — | CN | disclosed |
| US-8815930-B2 | Compounds that inhibit TRPV1 and uses thereof | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-7767705-B2 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| CN-101541758-A | Indazole derivatives that inhibit TRPV1 and uses thereof | ABBOTT LAB (US) | 2009-09-23 | — | — | CN | disclosed |
| EP-2054390-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | Abbott Laboratories (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008024945-A1 | INDAZOLE DERIVATIVES THAT INHIBIT TRPV1 AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-02-28 | — | — | WO | disclosed |
| US-5169958-A | Reacting, 3-amino-2-propen-1-ones with magnesium halide in solvent | BASF AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| EP-0480242-A2 | Method for the production of alpha,beta-unsaturated carbonyl compounds | BASF Aktiengesellschaft (DE) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249203-A1 | COMPOUNDS THAT INHIBIT TRPV1 AND USES THEREOF | TRPV1, TRPV3, TRPA1 | PDE2A 908/4885HTR2A 273/4885HTR2B 131/4885 |
| US-20080058401-A1 | 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea; transient receptor potential vanilloid-1 (TRPV1) antagonist; low inhibitory activity against drug metabolism enzyme CYP3A4; antinociceptive, analgesic, antiinflammatory, antischemic agent; neuropatic pain | TRPV1, TRPA1, OPRK1 | PDE2A 1776/4885HTR2A 657/4885HTR2B 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.